Rapid Analysis of Nitrosamines in Drug Product Using SIFT-MS

contributed by Syft Technologies | 12/09/2022

The presence of nitrosamines in drug products is a continuing challenge for the pharmaceutical industry (EMA (2021); US FDA (2021)). Golob et al. (2022) have provided an excellent, up-to-date overview of the history. A method for quantitation of N-nitrosodimethylamine (NDMA) direct from drug products using headspace- selected ion flow tube mass spectrometry (SIFT-MS) was described in a recent application note (Perkins and Langford (2022a)). There, two ranitidine drug products were used as part of method development. Although these were not from a recalled batch to the best of our knowledge, NDMA concentrations of 68 and 328 ng g-1, respectively, were detected.

Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE!

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

Receive communication from The Cannabis Scientist I want to stay up to date with the Mass Spectrometry field I want to stay up to date with the Spectroscopy field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.